Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

HeartSciences (HSCS) EBITDA Margin (2021 - 2025)

HeartSciences filings provide 5 years of EBITDA Margin readings, the most recent being 85713.23% for Q4 2025.

  • On a quarterly basis, EBITDA Margin changed N/A to 85713.23% in Q4 2025 year-over-year; TTM through Jan 2026 was 89939.57%, a 4525160.0% decrease, with the full-year FY2025 number at 192013.13%, down 15811114.0% from a year prior.
  • EBITDA Margin hit 85713.23% in Q4 2025 for HeartSciences, up from 98637.84% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 9011.84% in Q3 2021 to a low of 98637.84% in Q3 2025.
  • Median EBITDA Margin over the past 5 years was 44418.82% (2025), compared with a mean of 48780.2%.
  • Biggest five-year swings in EBITDA Margin: crashed -3567869bps in 2022 and later skyrocketed 5676700bps in 2024.
  • HeartSciences' EBITDA Margin stood at 9011.84% in 2021, then crashed by -396bps to 44690.53% in 2022, then grew by 10bps to 40254.95% in 2023, then surged by 74bps to 10376.75% in 2024, then tumbled by -726bps to 85713.23% in 2025.
  • The last three reported values for EBITDA Margin were 85713.23% (Q4 2025), 98637.84% (Q3 2025), and 44147.1% (Q2 2025) per Business Quant data.